Emergence of macrolide resistance and clinical use of macrolide antimicrobials in children.
10.3345/kjp.2008.51.10.1031
- Author:
Eun Hwa CHOI
1
Author Information
1. Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea. eunchoi@snu.ac.kr
- Publication Type:Review
- Keywords:
Macrolide;
Resistance;
Streptococcus pneumoniae;
Streptococcus pyogenes
- MeSH:
Anti-Bacterial Agents;
Anti-Infective Agents;
Azithromycin;
Binding Sites;
Child;
Clarithromycin;
Erythromycin;
Half-Life;
Humans;
Korea;
Macrolides;
Otitis Media;
Pneumonia;
Respiratory Tract Infections;
Ribosomes;
Roxithromycin;
Streptococcus pneumoniae;
Streptococcus pyogenes
- From:Korean Journal of Pediatrics
2008;51(10):1031-1037
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Macrolide antimicrobial agents including erythromycin, roxithromycin, clarithromycin, and azithromycin are commonly used in the treatment of respiratory tract infections in children. Newer macrolides that have structural modifications of older drug erythromycin show improved change in the spectrum of activity, dosing, and administration. However, recent studies reported that increasing use of macrolide antibiotics is the main force driving the development of macrolide resistance in streptococci. In particular, azithromycin use is more likely to select for macrolide resistance with Streptococcus pneumoniae than is clarithromycin use, a possible reflection of its much longer half life. Recently, erythromycin resistance rates of S. pneumoniae and Streptococcus pyogenes are rapidly increasing in Korea. Two main mechanisms of acquired macrolide resistance have been described, altered binding site on the bacterial ribosome encoded by the ermB gene and active macrolide efflux pump encoded by the mef gene. Relationship between the susceptibility of S. pneumoniae and the response to macrolides has been shown in studies of acute otitis media, but less clear in cases of pneumonia. This article reviews the spectrum of activity, pharmacokinetic properties, mechanisms of action and resistance, and clinical implication of resistance on the treatment of respiratory tract infections in children.
